Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Non-cash Items (2019 - 2025)

Cytosorbents' Non-cash Items history spans 7 years, with the latest figure at $1.5 million for Q4 2025.

  • Quarterly results put Non-cash Items at $1.5 million for Q4 2025, down 50.0% from a year ago — trailing twelve months through Dec 2025 was $1.5 million (down 50.0% YoY), and the annual figure for FY2025 was $1.5 million, down 50.0%.
  • Non-cash Items for Q4 2025 was $1.5 million at Cytosorbents, up from $4.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $8.0 million in Q3 2023 to a low of $4.0 in Q3 2025.
  • The 5-year median for Non-cash Items is $4.0 million (2021), against an average of $3.9 million.
  • The sharpest move saw Non-cash Items soared 75.22% in 2021, then plummeted 100.0% in 2025.
  • Year by year, Non-cash Items stood at $3.9 million in 2021, then changed by 0.0% to $3.9 million in 2022, then grew by 25.37% to $4.9 million in 2023, then plummeted by 38.37% to $3.0 million in 2024, then tumbled by 50.0% to $1.5 million in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $1.5 million, $4.0, and $1064.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.